Commercialization: Page 21
-
PharmaVoice Team/PharmaVoice
Upfront
Merck Debuts Documentary A Touch of Sugar Merck’s documentary film, A Touch of Sugar, debuted during the Tribeca Film Festival in April as a part of the company’s America’s Diabetes Challenge: Get to Your Goals. Narrated by award-winning actress and documentary spokesperson Viola Davis, the film ...
By PharmaVoice Team • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Last Word
Anything But Generic Leadership Marc Kikuchi, the newly appointed CEO of Dr. Reddy’s North America — and a 2015 PharmaVOICE 100 — discusses trends in the generics industry and how he is positioning the company for success. PV: What are some of the biggest issues impacting the U.S. generics indust...
By Marc Kikuchi • June 1, 2019 -
PharmaVoice Team/PharmaVoice
The Realities of VR and AR in the Industry
Pharma brings complicated material to life with augmented and virtual reality. Imagine you are standing in your exhibit booth on a very crowded scientific and educational meeting floor, armed with fascinating, yet difficult-to-understand medical content that needs to make its way to the many pass...
By Robin Robinson • June 1, 2019 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Clinical Trial Solutions: Technology the Key to Improving Efficiencies and Retention in Clinical Trials
The use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes. Most pharmaceutical companies and contract research organizations have adopted technology solutions, including electronic data capture solutions and clinical trial management ...
By PharmaVoice Team • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Addressing E6(R2) as an SMB: Why Small Pharma and Emerging Biotechs May be Falling Behind
It’s been three years since ICH added the E6 (R2) addendum to its Good Clinical Practice guidelines. The addendum was intended to create harmonization between US and EU clinical research regulations, and to drive adoption of quality risk management methodologies in clinical trial design, conduct,...
By Cheryle Evans • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Data Ownership: Setting Up Your Study for Success
A small-to medium-size biotech or medical device company typically succeeds or fails on one pivotal study. It cannot be underestimated how important the study and operational data are to the success of that organization. The paramount consideration needs to be, do you have ownership of that data?...
By Andrew Schachter • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Simplifying the Patient Experience Through Technology
Most businesses and individuals involved in clinical research would argue that an industry priority should be improving the patient experience. The reality, though, is often quite different. Patient focus potentially simplifies the research conducted today and accelerates potential future benefit...
By Mike Nolte • June 1, 2019 -
PharmaVoice Team/PharmaVoice
The Vital Role of Imaging in Clinical Trials
Technology and innovation are reshaping clinical trials. Nowhere is this more evident than in the use of imaging in drug and device research. Over the last 10 years imaging has evolved from mostly qualitative assessments to more and more truly quantitative measurements. This is driven by the incr...
By Amit Vasanji • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Increasing Predictability in Patient Recruitment
Protocol Complexity and Optimization According to industry research1 there is increasing complexity in protocol design. This same research suggests that the demands on patients participating in trials are rising as a result of this and that there has been 70% increase in the total number of patie...
By E.B. McLindon • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Virtual Trials Have (Finally) Arrived: How this remote model is transforming the clinical research experience, leading to lower costs and easier recruiting.
The pharma industry has been talking about the benefits of virtual trials for years, but it’s only recently that the promise of conducting complex efficacy studies in patients’ homes has finally become a reality. Industry leaders began singing the praises of virtual models around 2012, shortly af...
By Josh Rose • June 1, 2019 -
PharmaVoice Team/PharmaVoice
The AI Revolution in Multivigilance
Advanced Technology Helps Protect Patients and Billions in R&D Investment. Bringing a new medicine, medical device, vaccine, or combination product to market today requires enormous investment. PhRMA estimates that a new drug takes nearly a decade to make it from discovery to approval and an ...
By Bruce Palsulich • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Leveraging Patient-Centric Data Analytics to Accelerate Clinical Trials
We are all familiar with the figures — it takes over a decade and $2.6 billion to bring a new drug to market. While these objective statistics are daunting and do give pause, almost every life science professional will agree that they don’t begin to tell the true story of the human element below ...
By Crystal Black • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Clinical Trial Solutions: Technology Disrupters
The biopharma industry faces myriad challenges in the pursuit of its mission to bring new treatments to patients in need of cures, chief among them the “Iron Triangle" of time, cost, and quality with respect to clinical research. The cost of conducting clinical trials is escalating, quality remai...
By A.K. Gupta • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Marketing High Science Brands
The Challenge: Creating compelling campaigns for complex science Cancer immunotherapies and other high-science brands will be busting the market at $34 billion by 2024, according to GlobalData. As the science around these types of treatments continue to drastically change therapeutic options, the...
By Robin Robinson • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Charting Their Own Course
Every entrepreneur’s journey is as unique as he or she is. The common denominator: a passion to improve the lives of patients. Risk-takers, disrupters, change agents, visionaries — more than a dozen industry entrepreneurs discuss what it takes to make the bold step to create something new and th...
By PharmaVoice Team • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Speak Out
Disruptive Innovation Drives Positive Outcomes Best Practices for Adopting the Shared Investigator Platform The Cognizant Shared Investigator Platform – SIP – is the disruptive innovation our industry sorely needs to reduce the burden placed on sites conducting clinical trials. Stakeholders from ...
By Larissa Comis • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Executive Perspective
Transforming the Lives of Patients: A Conversation with Ron Menezes When Ron Menezes, President and General Manager of Almirall, LLC, took the helm of the U.S. market for the global, Spanish-based company, his mission was clear: become a leader in innovation in the dermatology market. The company...
By Ron Menezes • June 1, 2019 -
PharmaVoice Team/PharmaVoice
Last Word
MSL Certification Christine Megalla, Pharm.D., Associate Director of Educational Programs at the Accreditation Council for Medical Affairs, talks about the organization’s certification process. PV: What is the ACMA doing to ensure standards around the role of medical affairs, and why is this impo...
By Christine Megalla • May 1, 2019 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Connected Health: An Important Tool for Improving Outcomes
The digital age has put more data and insights into the hands of healthcare professionals and patients. Digital technologies — wireless, electronic, mobile, telehealth — have made connected health possible, with the objective of enhancing patient engagement and ultimately health outcomes. To dete...
By PharmaVoice Team • May 1, 2019 -
PharmaVoice Team/PharmaVoice
Connected Health — We Could Learn From Marvel Studios
Marvel Studios is about to release its last Avengers movie. It brings together the biggest superheroes from a myriad of universes for the final epic battle, connecting many storylines for one last big hit. Marvel has done quite a bit over the last 10 years to connect these superhero worlds, throu...
By Angelo Joseph Campano • May 1, 2019 -
PharmaVoice Team/PharmaVoice
Brand Bonds
Trust is the glue of agency/client relationships, and communication is the foundation. Browse a few pharma marketing agency websites and you can learn about the number of awards won, the big name clients, the years in business, the expertise; but where is the link for “Good at Relationships?" One...
By PharmaVoice Team • May 1, 2019 -
PharmaVoice Team/PharmaVoice
The Biosimilars Market
While the bulk of activity in the biosimilar space has taken place outside of the United States, the approval and uptake of biosimilars in the United States is expected to pick up over the next five years. The biosimilar industry has developed rapidly, and regulations have advanced significantly ...
By Denise Myshko • May 1, 2019 -
PharmaVoice Team/PharmaVoice
Speak Out
What do patients really want from pharma? Today, most of us have become digital natives—seamlessly integrating mobile experiences into our daily lives. Many of us are also patients and caregivers. This represents an opportunity for pharma to offer mobile-first approaches to engage healthcare cons...
By Hoss Sooudi • May 1, 2019 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The Patient Inside Us All… At some point in our lives we have been or will be a patient…and yet we are so much more. We are also parents, aunts, uncles, caregivers, in addition to the roles we embody as leaders in the healthcare ecosystem. We asked the patients interviewed for this second annual ...
By Taren Grom • April 1, 2019 -
PharmaVoice Team/PharmaVoice
Upfront
Amgen Supports STEM Education Amgen has become a pilot partner of STEMissaries, along with Science from Scientists (SfS), a nonprofit dedicated to empowering youth to remain competitive in emerging STEM fields. Together, Amgen, Amgen Foundation, and SfS are partnering on the STEMissaries program ...
By PharmaVoice Team • April 1, 2019
Previous
